comparemela.com

Latest Breaking News On - Cm management - Page 2 : comparemela.com

DURECT Co. (NASDAQ:DRRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of DURECT Co. (NASDAQ:DRRX – Get Free Report) have been given an average recommendation of “Moderate Buy” by the five analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price […]

Cm-management
Ironwood-investment-management
Investors-inc
Nasdaq
Richmond-brothers-inc
Get-free-report
Marketbeat-ratings
Investment-management
Get-free

Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a report released on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Pieris Pharmaceuticals Trading Down 0.1 % Shares of PIRS stock opened at $10.48 on Thursday. Pieris Pharmaceuticals has a twelve month low of $10.31 and […]

Boston
Massachusetts
United-states
Recherches-internationales-servier
Les-laboratoires-servier
Cm-management
Pieris-pharmaceuticals-inc
Pieris-pharmaceuticals-company-profile
Boston-pharmaceuticals
Acadian-asset-management
News-ratings-for-pieris-pharmaceuticals-daily
Pieris-pharmaceuticals

Pan American Silver (NYSE:PAAS) PT Raised to $23.00 at Scotiabank

Pan American Silver (NYSE:PAAS – Free Report) (TSE:PAAS) had its price target hoisted by Scotiabank from $20.00 to $23.00 in a research note issued to investors on Thursday morning, Benzinga reports. Scotiabank currently has a sector outperform rating on the basic materials company’s stock. Other equities research analysts have also issued reports about the stock. […]

Bolivia
Canada
Peru
United-states
Chile
Brazil
Argentina
Monaco
Mexico
American
Scotiabank

StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)

StockNews.com started coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Pieris Pharmaceuticals Stock Down 0.1 % NASDAQ PIRS opened at $10.48 on Thursday. The business’s 50-day moving average price is $12.87 and […]

Boston
Massachusetts
United-states
Recherches-internationales-servier
Les-laboratoires-servier
Acadian-asset-management
Pieris-pharmaceuticals-inc
News-ratings-for-pieris-pharmaceuticals-daily
Boston-pharmaceuticals
Pieris-pharmaceuticals
Institutional-trading-of-pieris-pharmaceuticals
Pfizer-inc

Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a research note released on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Pieris Pharmaceuticals Price Performance PIRS stock opened at $10.48 on Thursday. The firm has a market cap of $13.83 million, a price-to-earnings ratio of […]

Boston
Massachusetts
United-states
Recherches-internationales-servier
Les-laboratoires-servier
Institutional-trading-of-pieris-pharmaceuticals
Pfizer-inc
Pieris-pharmaceuticals
Pieris-pharmaceuticals-company-profile
Cm-management
News-ratings-for-pieris-pharmaceuticals-daily
Acadian-asset-management

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.